

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

Assignment ID: PATI9556

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Kadmon Pharmaceuticals, LLC	02/05/2024
RECEIVING PARTY DATA	
Company Name:	Kadmon Corporation, LLC
Street Address:	55 Corporate Drive
City:	Bridgewater
State/Country:	NEW JERSEY
Postal Code:	08807
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	16632659
PCT Number:	US1843331
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6174304740
Email:	docketing@mcneillbaur.com,mycklena.kosloski@mcneillbaur.com
Correspondent Name:	McNeill Baur PLLC
Address Line 1:	125 Cambridge Park Drive
Address Line 2:	Suite 301
Address Line 4:	Cambridge, MASSACHUSETTS 02140
NAME OF SUBMITTER:	Mycki Kosloski
SIGNATURE:	Mycki Kosloski
DATE SIGNED:	02/07/2024
Total Attachments: 5	
source=KAD-495 assignment from Kadmon Phrmaceuticals to Kadmon Corporation#page1.tif	
source=KAD-495 assignment from Kadmon Phrmaceuticals to Kadmon Corporation#page2.tif	
source=KAD-495 assignment from Kadmon Phrmaceuticals to Kadmon Corporation#page3.tif	
source=KAD-495 assignment from Kadmon Phrmaceuticals to Kadmon Corporation#page4.tif	
source=KAD-495 assignment from Kadmon Phrmaceuticals to Kadmon Corporation#page5.tif	

ASSIGNMENT

For valuable consideration, the receipt of which is hereby acknowledged, and intending to be bound legally **Kadmon Pharmaceuticals, LLC**, a corporation formed under the laws of Delaware and having a principal place of business at 55 Corporate Drive, Bridgewater, NJ 08807, USA (formerly domiciled at 450 East 29th Street, New York, New York 10016, USA) (the "Assignor"), assigns **Kadmon Corporation, LLC**, a corporation formed under the laws of Delaware and having a principal place of business at 55 Corporate Drive, Bridgewater, NJ 08807, USA, (formerly domiciled at 450 East 29th Street, New York, New York 10016, USA) and its successors, transferees, and assignees (collectively the "Assignee"), all of its rights, titles, and interests throughout the world in the invention(s) (the "Subject Matter") disclosed or claimed in the patents and applications listed in Schedule A (the "Patents and Applications").

This Assignment assigns, in addition to the Subject Matter, (a) the Patents and Applications and all other applications that may be made for, and all patents, utility models, design registrations, and other rights of exclusion and inventors' certificates for, any of the Subject Matter (collectively the "Patents, Applications, and Granted Rights") in every country or region, and under every treaty or convention, (b) the right to claim priority based on and the benefit of the filing date of any of the Patents, Applications, and Granted Rights under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, the Hague Agreement and all other applicable treaties or conventions, and (c) the right to pursue, collect, and retain in the Assignee's name or otherwise, damages and any other remedies arising from any past, present, or future infringement of the Subject Matter, the Patents, Applications, and Granted Rights, and any other rights assigned by this Assignment.

To the extent any portion of the rights assigned by this Assignment has previously been assigned to the Assignee, this Assignment is a confirmation of the previous Assignment.

Assignor authorizes the Assignee to apply for and pursue protection for any or all of the Subject Matter, the Patents, Applications, and Granted Rights, and any other rights assigned by this Assignment in all countries, regions, and territories of the world, in the Assignor's name or in the Assignee's name.

Assignor represents and warrants that it has the right and power to make this Assignment and that it has not made and will not make any other assignment that conflicts with this Assignment.

Assignor will communicate to the Assignee (or at the request of the Assignee to other parties) all known facts in any form relating to the Subject Matter, will execute and provide all oaths and declarations, statements, testimony, assignments, powers of attorney, applications, and documents, and will perform all other lawful acts necessary or desirable to secure fully to the Assignee the rights, titles, and interests assigned by this Assignment.


Kadmon Pharmaceuticals, LLC (the "Assignor")

Signed at Austin, TX USA on this 5th day of February, 2024.
(City, State and Nation)

By: _____

Print Name: Olivier Bogillot

Title: Head of North America General Medicines



Kadmon Corporation, LLC (the "Assignee") hereby acknowledges and accepts the foregoing assignment.

Signed at _____ on this _____ day of _____, 2024.
(City, State and Nation)

By: _____

Print Name: _____

Title: _____

Assignor represents and warrants that it has the right and power to make this Assignment and that it has not made and will not make any other assignment that conflicts with this Assignment.

Assignor will communicate to the Assignee (or at the request of the Assignee to other parties) all known facts in any form relating to the Subject Matter, will execute and provide all oaths and declarations, statements, testimony, assignments, powers of attorney, applications, and documents, and will perform all other lawful acts necessary or desirable to secure fully to the Assignee the rights, titles, and interests assigned by this Assignment.

Kadmon Pharmaceuticals, LLC (the "Assignor")

Signed at _____ on this _____ day of _____, 2024.
(City, State and Nation)

By: _____

Print Name: _____

Title: _____

Kadmon Corporation, LLC (the "Assignee") hereby acknowledges and accepts the foregoing assignment.

Signed at Paris, France on this 7 day of February, 2024.
(City, State and Nation)

By: _____

Print Name: _____

Title: _____

Muriel MOREL-PECHNIK
Head of Synthetic Molecules Patents

SCHEDULE A

<u>Pat./Pub. No.</u>	<u>App. No.</u>	<u>Country</u>	<u>Filing Date</u>	<u>Title</u>
	3,070,112	Canada	23/07/2018	Inhibitors Of Rho Associated Coiled-Coil Containing Protein Kinase
111278437A	201880056445.8	China	23/07/2018	Inhibitors Of Rho Associated Coiled-Coil Containing Protein Kinase
202090304	202090304	Eurasia	23/07/2018	Inhibitors Of Rho Associated Coiled-Coil Containing Protein Kinase
	202390675	Eurasia	26/05/2023	Inhibitors Of Rho Associated Coiled-Coil Containing Protein Kinase
3654972	18835594.5	Europe	23/07/2018	Inhibitors Of Rho Associated Coiled-Coil Containing Protein Kinase
40030458A	62020020818.4	Hong Kong	23/07/2018	Inhibitors Of Rho Associated Coiled-Coil Containing Protein Kinase
2020-528415	2020-502698	Japan	23/07/2018	Inhibitors Of Rho Associated Coiled-Coil Containing Protein Kinase
2023-033316	2022-204690	Japan	21/12/2022	Inhibitors Of Rho Associated Coiled-Coil Containing Protein Kinase
	62/535,603	USA	21/07/2017	Inhibitors Of Rho Associated Coiled-Coil Containing Protein Kinase
US-2021-0163421-A1	16/632,659	USA	23/07/2018	Inhibitors Of Rho Associated Coiled-Coil Containing Protein Kinase
WO/2019/018853	PCT/US2018/043331	WO	23/07/2018	Inhibitors Of Rho Associated Coiled-Coil Containing Protein Kinase

--	--	--	--	--